Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Hepatocellular 2Rare Malignant Neoplasm 1Myeloproliferative Disorders 1Melanoma 1Immunoglobulin Light-chain Amyloidosis 1Hereditary Sensory and Autonomic Neuropathies 1Hepatitis B 1Dysplastic Nevus Syndrome 1Complicated Adrenal Tumor Diseases 1Colorectal Adenocarcinoma 1Brain Neoplasms 1

Interventions

Blood Specimen Collection 14Nivolumab 13Ipilimumab 12pembrolizumab 11trametinib 9Surveys and Questionnaires 9Gene Expression Profiling 9dabrafenib 8Biopsy 6Specimen Handling 5Immunotherapy 5Immunohistochemistry 5Amplified Fragment Length Polymorphism Analysis 4encorafenib 3binimetinib 3atezolizumab 3Restraint, Physical 3Quality of Life 3Polymerase Chain Reaction 3Introns 3Flow Cytometry 3Drug Therapy 3Data Collection 3tremelimumab 2pimonidazole 2cobimetinib 2aldesleukin 2Watchful Waiting 2Vemurafenib 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Melanoma × Pharmaceutical Preparations × Clear all
NCT06599619 2026-01-26

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

University of Pittsburgh

Recruiting
30 enrolled
Dermatologic

Dysplastic Nevus Syndrome, Melanoma, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡